|Bid||11.81 x 800|
|Ask||0.00 x 800|
|Day's Range||11.58 - 12.03|
|52 Week Range||10.91 - 39.33|
|Beta (3Y Monthly)||0.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.67|
NEW YORK , Oct. 3, 2019 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international securities and consumer rights litigation firm, is investigating whether certain directors ...
ALACHUA, Fla., Sept. 19, 2019 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to.
NEW YORK, Sept. 11, 2019 -- Bragar Eagel & Squire is investigating certain officers and directors of Mammoth Energy Services, Inc. (NASDAQ: TUSK), Acer Therapeutics, Inc..
Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that it will participate in the 74th Annual Meeting of the American Society for Surgery of the Hand (ASSH) from September 4-7 in Las Vegas. The meeting is the largest international gathering of hand surgeons and features scientific sessions, training opportunities, poster presentations, and exhibits. Axogen is an elite partner for the meeting and will host a lunch symposium and panel discussion on Friday, September 6 from 12:00 – 1:00 p.m. The symposium, Minimizing Variability in Order to Maximize Outcomes in Peripheral Nerve Repair, will include a discussion with three of the country’s leading nerve surgeons.
Bragar Eagel & Squire is investigating certain officers and directors of Lannett Company, Inc. (LCI), Molson Coors Brewing Company (TAP), AxoGen, Inc. (AXGN), and American Renal Associates Holdings, Inc. (ARA) on behalf of long-term stockholders. Bragar Eagel and Squire is investigating certain officers and directors of Lannett Company, Inc. following a class action complaint that was filed against Lannett on November 16, 2016.
CEO of Axogen Inc (30-Year Financial, Insider Trades) Karen L. Zaderej (insider trades) bought 75,000 shares of AXGN on 08/09/2019 at an average price of $13.5 a share. Continue reading...
AxoGen (AXGN) delivered earnings and revenue surprises of 23.08% and -0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALACHUA, Fla., July 29, 2019 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral.
SAN DIEGO , July 26, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by AxoGen, Inc. ("AxoGen") (NASDAQ: AXGN) and ...
ALACHUA, Fla., July 26, 2019 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral.
Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET. Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.
NEW YORK, July 22, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of AxoGen (NASDAQ: AXGN). According to.
NEW YORK, July 19, 2019 -- Levi & Korsinsky announces it has commenced an investigation of AxoGen, Inc. (NASDAQCM: AXGN) concerning possible breaches of fiduciary duty. To.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Is AxoGen, Inc. (NASDAQ:AXGN) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]
Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that members of its management team will participate in three upcoming investor conferences during June. Karen Zaderej, chairman, CEO, and president will present at the Jefferies 2019 Healthcare Conference in New York City. Peter J. Mariani, chief financial officer, will present at the William Blair 39th Annual Growth Stock Conference in Chicago.